Takeda: Prostatic Neoplasms trials

The registry lists 20 Prostatic Neoplasms studies with Takeda as lead sponsor. 0 are open to participants now and 12 have results posted.

Phase 1 8Phase 2 11Phase 3 5No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer"CompletedNCT03209492Results posted
• Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Survey in Prostate Cancer Patients (96 Weeks)"CompletedNCT02167893Results posted
• A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate CancerCompletedNCT02141659Phase 1Results posted
• Safety and Efficacy of TAK-385 for Patients With Localized Prostate CancerCompletedNCT02135445Phase 2Results posted
• A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate CancerCompletedNCT02085252Phase 3Results posted
• A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate CancerCompletedNCT02083185Phase 2Results posted
• Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate CancerCompletedNCT01666314Phase 1/2Results posted
• Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT01549951Phase 2Results posted
• A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal TherapyCompletedNCT01546623Phase 3Results posted
• Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.CompletedNCT01193257Phase 3Results posted
• Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate CancerCompletedNCT01193244Phase 3Results posted
• Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate CancerCompletedNCT01084655Phase 1/2Results posted
• Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448TerminatedNCT01132404Phase 1/2
• Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate CancerCompletedNCT01122121Phase 3
• Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific AntigenCompletedNCT01046916Phase 2
• Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,cCompletedNCT00817739Phase 2
• Safety Study of TAK-700 in Subjects With Prostate Cancer.CompletedNCT00569153Phase 1/2
• MLN2704 in Subjects With Metastatic Androgen-Independent Prostate CancerCompletedNCT00070837Phase 1/2
• Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate CancerCompletedNCT00064610Phase 1/2
• A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate CancerCompletedNCT00052000Phase 1